Référence
1 Pour mieux soigner, des médicaments à écarter: bilan 2023. Rev Prescrire 2022;42(470):936–948. https://www.prescrire.org/Fr/202/1844/60442/0/PositionDetails.aspx
1 Kronenberg G, Colla M, Offenhammer B, Olbrich S, Seifritz E. Therapieresistente Depression – «State-of-the-art»-Psychopharmakotherapie und Zukunftsperspektiven. Swiss Med Forum. 2023;23(3):842–5.
2 Sharman Moser S, Chodick G, Gelerstein S, Barit Ben David N, Shalev V, Stein-Reisner O.Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. BMC Psychiatry. 2022;22(1):541.
3 Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS One. 2019;14(10):e022325.5
4 Sapkota A, Khurshid H, Qureshi IA, Jahan N, Went TR, Sultan W, Alfonso M. Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review. Cureus. 2021;13(8):e17352.
5 https://clinicaltrials.gov/ct2/show/NCT02782104 (abgerufen am 28. Januar 2023)
6 Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021;21(1):526.
7 Liu P, Zhang SS, Liang Y, Gao ZJ, Gao W, Dong BH. Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis. Neuropsychiatr Dis Treat. 2022;18:2855–65.